Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of LVGN6051 + toripalimab + paclitaxel in recurrent/metastatic head and neck squamous cell carcinoma
CTR20241055Phase 2Active
- Sponsor
- Lijin Biotech
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of exlinkibart in head and neck squamous cell carcinoma (HNSCC), sponsored by Lijin Biotech. Started Jun 2024; status: active.
02
Drugs
exlinkibart
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20241055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241055.